Lupus is an chronic autoimmune disease in which the immune system of the body mistakenly attacks healthy tissues and organs. The standard treatments for lupus involves immunosuppressant medications to reduce inflammation and pain caused by the disease. However, recent years have witnessed significant rise in research and development investments by pharma companies in developing novel targeted treatment therapies for lupus. Several biologics and small molecule inhibitors are currently under clinical trials that promises higher efficacy and reduced side effects.
Lupus can affect multiple organs like joints, skin, kidneys, blood cells, brain, heart and lungs. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, abdominal pain, feeling tired, skin rashes. The standard lupus treatment include corticosteroids to reduce inflammation, hydroxychloroquine and immunosuppressants like azathioprine to control disease activity. Biologic therapies inhibiting specific cytokines and signaling molecules implicated in autoimmunity are promising novel treatment alternatives.
The global Lupus Therapeutic Market is estimated to be valued at US$ 30 billion in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing R&D Investments: Significant rise in research funding and partnerships between pharma companies and clinical research organizations is fueling the development of novel biologics, immunotherapies and DNA/RNA-based treatments for lupus. For instance, Anthropic secured $135 million funding in 2022 to accelerate AI-based drug discovery including for lupus.
Disease Burden: The increased prevalence of lupus globally due to genetic and environmental factors is boosting the demand for more effective treatment regimens with minimal side effects. As per Lupus Foundation of America, about 1.5 million Americans and at least 5 million people worldwide suffer from a form of lupus.
Segment Analysis
The global lupus therapeutic market is bifurcated into drug class and distribution channel. Based on drug class, the market is segmented into NSAIDs, corticosteroids, immunosuppressive drugs, biologics and others. Corticosteroids segment held the largest market share in 2022 and is expected to remain dominant during the forecast period. Corticosteroids helps in reducing inflammation, pain and other symptoms related to lupus. Hence, corticosteroids segment dominates the lupus therapeutic market.
PEST Analysis
Political: Government initiatives to increase awareness about lupus and funds for research & development activities positively impact the market. Stringent regulations for approval of drugs may hinder the market growth.
Economic: Rising geriatric population suffering from lupus and improving healthcare infrastructure and services drive the market. However, high treatment costs of biologics hamper the market growth.
Social: Increasing prevalence of lupus, growing health consciousness, and financial support from societies & associations support the market growth.
Technological: Advancements in drug delivery methods and focus on development of novel targeted therapies boost the market. Development of combination therapies and personalized medicines offer lucrative opportunities.
Key Takeaways
The Global Lupus Therapeutic Market Growth is expected to witness high at a CAGR of 5.6% during the forecast period of 2023 to 2030.
Regional analysis: North America holds the largest share in the global lupus therapeutic market due to rising healthcare expenditure, presence of well-established players, and growing awareness about lupus.
Key players: Key players operating in the lupus therapeutic market are Pfizer, Merck, Bristol-Myers Squibb, GlaxoSmithKline, F. Hoffmann-La Roche, Eli Lilly and Company. Pfizer leads the global market share with its blockbuster drug Benlysta, approved for treating lupus.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
